Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden and endotoxin risks.

Manufacturing difficulties are holding back the commercial development of heart disease cell therapies, according to researchers who say “cell free” treatment could be an easy-to-make alternative.

Judge to temporarily block Trump order ending birthright citizenship in nationwide class action lawsuit.